Estrogen-progestin therapy in women after stem cell transplant: Our experience and literature review

Menopause

Volumn 14, Issue 2, 2007, Pages 320-330

  Tauchmanovà, Libuse ^a   Selleri, Carmine ^a   De Rosa, Gennaro ^a   Sammartino, Annalidia ^a   Di Carlo, Costantino ^a   Musella, Tittania ^a   Martorelli, Carmen ^a   Lombardi, Gaetano ^a   Rotoli, Bruno ^a   Nappi, Carmine ^a   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Dydrogesterone; Estradiol; Hematopoietic stem cell transplant; Premature ovarian failure

Indexed keywords

BUSULFAN; CARMUSTINE; CETRORELIX; CHLORMETHINE; CHOLESTEROL; CYCLOPHOSPHAMIDE; CYTARABINE; DYDROGESTERONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETOPOSIDE; GESTAGEN; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; MELPHALAN; NORETHISTERONE ACETATE; PREDNISONE; PROCARBAZINE; TRIACYLGLYCEROL; TRIPTORELIN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMENORRHEA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG WITHDRAWAL; ECHOGRAPHY; ESTROGEN DEFICIENCY; FEMALE INFERTILITY; GASTROINTESTINAL SYMPTOM; GONADOTROPIN BLOOD LEVEL; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOCOLPOMETRA; HODGKIN DISEASE; HUMAN; LITERATURE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; OVARY FOLLICLE; OVARY INSUFFICIENCY; PATIENT COMPLIANCE; PILOT STUDY; POLYMENORRHEA; PREMATURE OVARIAN FAILURE; RADIATION DOSE; RADIATION INJURY; REVIEW; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

DRUG THERAPY, COMBINATION; DYDROGESTERONE; ESTRADIOL; FEMALE; HUMANS; LEUKEMIA; OVARIAN FAILURE, PREMATURE; STEM CELL TRANSPLANTATION;

EID: 34247587740     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000232032.84788.8c     Document Type: Review

References (67)

1. Brennan B, Shalet SM. Endocrine late effects after bone marrow transplant. Br J Haematol 2002;118:58-66.
2. Tauchmanovà L, Selleri C, De Rosa G, et al. Gonadal status in reproductive aged women after stem cell transplantation for haematological malignancies. Hum Reprod 2003;18:1410-1416.
3. Grigg AP, McLachlan R, Zaja J, Szer J. Reproductive status in long-term bone marrow transplant survivors receiving busulphancyclophosphamide (120 mg/kg). Bone Marrow Transplant 2000;26:1089-1095.
4. Mertens AC, Ramsy NKC, Kouris S, Neglia JP. Patterns of gonadal dysfunction following bone marrow transplantation. Bone Marrow Transplant 1998;22:345-350.
5. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-233.
6. Byrne J, Lewis MES, Halamek L, et al. Childhood cancer survivors' knowledge of their diagnosis and treatment. Ann Intern Med 1989;110:400-403.
7. Warne GT, Fairley KF, Hobbs JB, Martin FIR. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973;289:1159-1162.
8. Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer 1985;55:2364-2372.
9. Siris ES, Leventhal BG, Vaitukaitis JL. Effects of childhood leukemia and chemotherapy on puberty and reproductive function in girls. N Engl J Med 1976;294:1143-1146.
10. Herschlag A, Schuster MW. Return of fertility after autologous stem cell transplantation. Fertil Steril 2002;77:419-421.
11. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-2370.
12. Epstein RJ. Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol 1990;8:2062-2084.
13. Stillman RJ, Schinfeld JS, Schiff I, et al. Ovarian failure in longterm survivors of childhood malignancy. Am J Obstet Gynecol 1981;139:62-66.
14. Schilsky RL, Sherins RJ, Hubbard SM, et al. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med 1981;71:552-556.
15. Quigley C, Cowell C, Jimenez M, et al. Normal or early development of puberty despite gonadal damage in children treated for acute lymphoblastic leukemia. N Engl J Med 1989;321:143-151.
16. Couto-Silva AC, Trivin C, Thibaud E, Esperou H, Michon J, Brauner R. Factors affecting gonadal function after bone marrow transplantation. Bone Marrow Transplant 2001;28:67-75.
17. Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF. Ovarian function after autologous bone marrow transplantation in childhood: high dose busulphan is a major cause of ovarian failure. Bone Marrow Transplant 1998;22:989-994.
18. Baker TG. Radiosensitivity of mammalian oocytes with particular reference to the human female. Am J Obstet Gynecol 1971;110:746-761.
19. Wallace WHB, Shalet SM, Hendry JH, Morris-Jones PH, Gattamaneni HR. Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin Oncol 1989;1:75-79.
20. Ash P. The influence of radiation on fertility in man. Br J Radiol 1980;53:271-278.
21. Horning SJ, Hoppe RT, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981;304:1377-1382.
22. Green DM, Yakar D, Brecher ML, Lindsay AN, Voorhess ML, MacGillivray MH. Ovarian function in adolescent women following successful treatment for non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol 1983;5:27-31.
23. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod 2001;7:535-543.
24. Sanders JE, Hawley J, Levy W, et al. Pregnancies following highdose cyclophosphamide with or without high-dose busulphan or total-body irradiation and bone marrow transplantation. Blood 1996;87:3045-3052.
25. Chatterjee R, Mills W, Katz M, McGarrigle HH, Goldstone AH. Prospective study of pituitary-gonadal function to evaluate shortterm effects of ablative chemotherapy or total body irradiation with autologous or allogenic marrow transplantation in postmenarcheal female patients. Bone Marrow Transplant 1994;13:511-517.
26. Sanders JE, Buckner CD, Amos D, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 1988;6:813-818.
27. Tauchmanovà L, Selleri C, Rotoli B, Lombardi G, Colao A. Endocrine consequences of the stem cell transplantation for hematological malignancies. Res Adv Cancer 2003;3:207-217.
28. Tauchmanovà L, Selleri C, De Rosa G, et al. Endocrine disorders during the first year after autologous stem-cell transplant. Am J Med 2005;118:664-670.
29. Herschlag A, Schuster M. Return of fertility after autologous stem cell transplantation. Fertil Steril 2002;77:419-421.
30. Schimmer AD, Quatermain M, Imrie K, et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol 1998;16:2359-2363.
31. Hägglund H, Remberger M, Klaesson S, Lönnqvist B, Ljungman P, Rindgden O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998;92:4568-4572.
32. Sica S, Salutari P, Chiusolo P, et al. Hormonal therapy after stem cell transplantation and the risk of veno-occlusive disease [letter]. Blood 1999;93:3154.
33. Laufer MR, Townsend NL, Parsons KE, et al. Inducing amenorrhea during bone marrow transplantation: a pilot study of leuprolide acetate. J Reprod Med 1997;42:537-541.
34. Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985;45:3651-3656.
35. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropinreleasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996;11:1620-1626.
36. Ledger WL, Thomas EJ, Browning D, Lenton EA, Cooke ID. Suppression of gonadotropin secretion does not reverse premature ovarian failure. Br J Obstet Gynaecol 1989;96:196-199.
37. Chiusolo P, Salutari P, Sica S, et al. Luteinizing hormonereleasing hormone analogue: leuprorelin acetate for prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. Bone Marrow Transplant 1998;21:821-823.
38. Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987;19:159-162.
39. Mardesic T, Snajderova M, Sramkova L, Keslova P, Sedlaced P, Stary J. Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. Eur Gynaecol Oncol 2004;25:90-92.
40. Johnson J, Bagley J, Skaznik-Wikiel M, et al. Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. Cell 2005;122:303-315.
41. Tauchmanovà L, Selleri C, Di Carlo C, et al. Estrogen-progestogen induced hematocolpometra following allogeneic stem cell transplant. Gynecol Oncol 2004;93:112-115.
42. Costantini S, Chiodi S, Spinelli S, et al. Complete vaginal obstruction caused by chronic graft-versus-host-disease after haematopoietic stem cell transplantation: diagnosis and treatment. J Obstet Gynaecol 2004;24:591-595.
43. Corson SL, Sullivan K, Batzer F, August C, Storb R, Thomas ED. Gynecologic manifestation of chronic graft-versus-host disease. Obstet Gynecol 1982;60:488-492.
44. Spinelli S, Chiodi S, Costantini S, et al. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica 2003;88:1163-1168.
45. Kolb HJ, Socié G, Duell T, et al, for the Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effects Project Group. Malignant neoplasms in long-term survivors of bone marrow transplantation. Ann Intern Med 1999;131:738-744.
46. Curtis RE, Rowling RA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997;336:897-904.
47. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration: bioidentical hormones. Am J Med 2005;118(12 Suppl 2):64-73.
48. Machens K, Schmidt-Gollwitzer K. Issues to debate on the Women's Health Initiative (WHI) study: hormone replacement therapy: an epidemiological dilemma? Hum Reprod 2003;18:1992-1999.
49. Salooja N, Szydlo RM, Sociè G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001;358:271-276.
50. Sanders JE, Hawley J, Levy W, et al. Pregnancies following highdose cyclophosphamide with or without high-dose busulphan or total-body irradiation and bone marrow transplantation. Blood 1996;87:3045-3052.
51. Chatterjee R, Kottaridis PD. Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for hematological malignancies. Bone Marrow Transplant 2002;30:629-635.
52. Balleari E, Garre S, Van Lint MT, et al. Hormone replacement therapy and chronic graft-versus-host disease activity in women treated with bone marrow transplantation for hematologic malignancies. Ann N Y Acad Sci 2002;966:187-192.
53. Marchesoni D, Dal Pozzo M, Dal Magro L, et al. Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause. J Endocrinol Invest 1996;19:268-272.
54. Gelfand M, Fugere P, Bissonnette F. Cardiovascular risk factors during sequentially combined 17β oestradiol and dydrogesterone (Femoston®); results from a one-year study in postmenopausal women. Maturitas 1997;26:125-132.
55. Schubert MA, Sullivan KM, Schubert MM, et al. Gynecological abnormalities following allogeneic bone marrow transplantation. Bone Marrow Transplant 1990;5:425-430.
56. Piccioni P, Scirpa P, D'Emilio I, et al. Hormonal replacement therapy after stem cell transplantation. Maturitas 2004;49:327-333.
57. Spinelli S, Chiodi S, Bacigalupo A. Ovarian recovery after total body irradiation and allogeneic bone marrow transplantation: long term follow up of 79 females. Bone Marrow Transplant 1994;14:373-380.
58. Tauchmanovà L, Serio B, Musella T, et al. Effects of different anti-reabsorbtive treatments on bone mineral density in women with precocious ovarian failure after allogeneic stem cell transplantation. Bone Marrow Transplant 2006;37:81-88.
59. Tauchmanovà L, Serio B, Del Puente A, et al. Long-lasting bone damage detected by dual energy x-ray absorptiometry, phalangeal osteosonogrammetry and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2002;87:5058-5065.
60. Ebeling PR. Defective osteoblast function may be responsible for bone loss from the proximal femur despite pamidronate therapy [editorial]. J Clin Endocrinol Metab 2005;90:4414-4416.
61. Castelo-Branco C, Rovira M, Pons F, et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 1996;23:307-312.
62. Ebeling PR. Bone disease after bone marrow transplantation. In: Compton J, Shane E, eds. Bone Disease of Organ Transplantation. Burlington, MA: Elsevier Academic Press, 2005: 339-351.
63. Tauchmanovà L, De Rosa G, Serio B, et al. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer 2003;97:2453-2461.
64. Miller KK, Klibanski A. Clinical review 106: amenorrheic bone loss. J Clin Endocrinol Metab 1999;84:1775-1783.
65. Gambacciani M, Monteleone P, Ciaponi M, Sacco A, Genazzani AR. Effects of oral contraceptives on bone mineral density. Treat Endocrinol 2004;3:191-196.
66. Kaupilla M, Koskinen P, Irjala K, Remes K, Viikari J. Long-term effects of allogeneic bone marrow transplantation (BMT) on pituitary, gonad, thyroid and adrenal function in adults. Bone Marrow Transplant 1998;22:331-337.
67. Keiholz U, Kõrbling M, Fehrentz D, Bauer H, Hunstein W. Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders. Cancer 1989;64:641-645.